Dr. Thomas Yarbrough Joins PetVivo Holdings, Inc. as the Senior Research Director
June 05 2023 - 10:55AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company")
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals and animal athletes is pleased to announce
that Dr. Thomas Yarbrough has accepted a position with the Company
as its new Senior Research Director.
"Tom is a key addition to our research and
development team,” said John Lai, Chief Executive Officer of
PetVivo Holdings, Inc. “Tom’s prior experiences as an experienced
practicing veterinarian and investigative scientist in the equine
and small animal sectors provides our team a known leader in the
industry as well as a tremendous research resource for our
company.”
Dr. Yarbrough is a board-certified Equine
surgeon with 30 years of experience working on high level
performance horses within all disciplines. He began his career
developing a referral base while working in research under the
esteemed Dr. Hari Reddi at the Center for Tissue Regeneration and
repair at the UC Medical center. His research with Hari centered
around an understanding of the changing genetic expression in
chondrocytes as they reformed their new nanostructure when
suspended in materials for later use in joint resurfacing.
Throughout his career he has stayed peripherally involved in
research both from the bench-top to the clinic. This research has
involved projects from the use and development of robotics in
surgical applications and advanced imaging to testing and
optimization of novel medications and devices for the management of
osteoarthritis. Although varied in scope his primary research
interests and passion has always involved the arena of management
of osteoarthritis. Colleagues that know him know he is an open
skeptic very slow to follow the new trends that frequent the
veterinary space. He comes on board with PetVivo with excitement to
take his knowledge of joint physiology and biology and put it to
use as the Company continues to understand the mechanisms of action
of Spryng in patients with joint pain.
“I am very excited to join the PetVivo
manufacturing, research and development team to assist in better
understanding their innovative veterinary medical device, Spryng
with OsteoCushion Technology, as well as participate in the
development and commercialization of the Company’s new life
changing therapeutic products” said Dr. Yarbrough. “I believe
PetVivo’s platform technology has the potential to improve the
medical outcome of humans and animals that suffer from one or more
debilitating afflictions related to joint dysfunction or
abnormality, thereby enhancing their lives.”
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024